CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review
Abdisa Tufa Bedada, Mohammed Mehdi, Ousman Mohammed · 2026
Read CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review by Abdisa Tufa Bedada, Mohammed Mehdi, Ousman Mohammed (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13394578.txt.
Description
Abdisa Tufa Bedada and colleagues review CAR-T cell therapy in cancer immunotherapy in a 2026 paper. Engineered T cells redirected against tumor antigens have transformed care for relapsed blood cancers, yet design, manufacturing, resistance, and toxicity questions remain.
The review traces CAR architecture from first-generation constructs to armored and fifth-generation designs, compares viral and non-viral gene delivery, and surveys in vivo engineering, off-the-shelf allogeneic products, logic-gated receptors, and safety switches. Readers gain a full tour of how CAR-T works, where it succeeds, and what must improve next.
Catalog record
| CREATOR | Abdisa Tufa Bedada, Mohammed Mehdi, Ousman Mohammed |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |